search
Back to results

Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)

Primary Purpose

Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP

Status
Not yet recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Telemonitoring
Standard-of-care
Sponsored by
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Atypical Parkinsonism focused on measuring Atypical parkinsonism, Nurse Specialist, MSA, PSP

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of MSA or PSP in all their possible variants (MSA-P, MSA-C; PSP-RS, PSP-P, PSP-CBS, etc.) according to internationally validated criteria. Exclusion Criteria: Hoehn and Yahr stage = 5 in ON phase Clinical Frialty Scale (CFS) ≥ 8 Serious medical disorders that, in the opinion of the recruiting neurologist, may impair participation in the study

Sites / Locations

  • Azienda Ospedaliera Universitaria Gaetano Martino
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
  • Fondazione IRCCS Istituto Neurologico Nazionale Casmiro Mondino
  • IRCCS Neuromed

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Telemonitoring

Standard-of-care

Arm Description

Patients are followed up by a nurse-telemonitoring

Patients are followed up only by the neurologist

Outcomes

Primary Outcome Measures

Changes in total score of the Parkinson's Disease Questionnaire 39-items scale (PDQ-39)
Thi is a 39-items questionnaire assessing the quality of life of patient with Parkinsonism. Score is expressed in percentage from 0% to 100%. The higher the score the lower the quality of life

Secondary Outcome Measures

Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part II (MDS-UPDRS Part II)
This is a scale (MDS-UPDRS Part II) used to assess activities of daily living. Score ranges from 0 to 52. The higher the score the worse the Disability
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part IV (MDS-UPDRS part IV)
This is a scale (MDS-UPDRS part IV) used to assess complications of dopaminergic therapy. Score ranges from 0 to 24. The higher the score the worse the disability
Changes in the Non-Motor Symptoms Scale score (NMSS)
This is a scale used to assess the burden of non-motor symptoms in Parkinson's disease. Total score is 0-360. The higher the score the worse the disability
Changes in Unified Multiple System Atrophy Rating Scale (UMSARS)
This scale (UMSARS) is used to assess disease progression in multiple system atrophy.The score is from 0 up to 109. The higher the score the worse the disability
Changes in Progressive Supranuclear Palsy Rating Scale (PSPRS)
This scale (PSPRS) is used to assess disease progression in Progressive Supranuclear Palsy. The total score is 0-100. The higher the score the worse the disability
Changes in the activities of daily living questionnaire (ADL_questionnaire)
The "ADL (Activities of Daily Living)" evaluation refers to the fundamental activities of daily life in which the subject is dependent: on a scale from 0 to 6 points, the lower the score, the greater the person's need for assistance
Changes in the intrumental activities of daily living questionnaire (IADL)
The "IADL (Instrumental Activities of Daily Living)" evaluation refers to the instrumental activities of daily life in which the subject is dependent (eg using telephone, preparing meals, taking medications, etc): on a scale from 0 to 8 points, the lower the score, the greater the person's need for assistance
Changes in the Zarit Burden Interview scale score (ZBI)
This is a scale used to investigate caregiver's burnout. Total score is 0-40. The higher the score the worse the disability
Number of unplanned hospital admission
Sum of number of outpatients departments assessments, number of emergency rooms accesses, number of unplanned hospitalizations
Number of incident comorbidities
The number of incident comorbidities over the 12.month study period will be assessed using a semistructured interview
Changes in Euro Quality Of Life Dimensions-5 Levels score (EuroQOL-5)
This is a useful and validated instrument to measure quality of life in patients with Parkinson's disease. The patient select a score from 0 to 100. The lowest the score the lowest quality of life.
Changes in the Morisky Medical Adherence scale-8 items score (MMAS)
This is an 8-items scale used to investigate patient adherence to the therapy prescribed by the MD specialist. Score is 0-8 "yes" answer. The 3 categorical Likert Scale is: low adherence <6; medium adherence 6-8; high adherence 8.
Changes in patient experience questionnaire (EQ)
This is a questionnaire assessing patient perception and satisfaction of the quality of health care. Total score is 0-100. The highest the score, the worst the satisfaction
Changes in freezing of walking, Freezing of gait-questionnaire (FOG-Q)
Changes in gait performances, mainly in freezing of walking, are analysis by this questionnaire. Total score is 0-24. The highest the score, the highest the freezing

Full Information

First Posted
February 24, 2023
Last Updated
May 8, 2023
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
Fondazione IRCCS Istituto Neurologico Nazionale Casmiro Mondino, Neuromed IRCCS, Azienda Ospedaliera Universitaria Gaetano Martino, Messina
search

1. Study Identification

Unique Protocol Identification Number
NCT05792332
Brief Title
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
Official Title
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing. A Multicenter, Interventional Non-pharmacological, Randomized, Single-blind Clinical Trial. IMPACT Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 15, 2023 (Anticipated)
Primary Completion Date
April 15, 2025 (Anticipated)
Study Completion Date
May 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
Fondazione IRCCS Istituto Neurologico Nazionale Casmiro Mondino, Neuromed IRCCS, Azienda Ospedaliera Universitaria Gaetano Martino, Messina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of life of patients with atypical parkinsonisms. This could reduce the risk (e.g. through health education counselling) and the severity of complications (e.g. falls). Main responsibilities of the Co-PI: project idea and supervision, coordination of the study, patient selection and recruitment, patient recruitment, participation in statistical analysis and drafting the manuscript. Co-PI is responsible of the rate of recruitment and drop-out
Detailed Description
People with parkinsonism experience a wide range of motor and non-motor disorders associated with the increasing complexity of care delivery and the increased risk of complications with increased hospital access. Although a number of multidisciplinary care models have been proposed so far, results have been disappointing in terms of benefit in quality of life and cost-effectiveness. An integrated remote care model at home, involving a parkinsonism nurse specialist (PKNS) as well as a movement disorder specialist, could offer significant benefits to patients and healthcare professionals through better health education, continuity of care and more careful monitoring of the complications of the accident. In this multicenter, randomized, single-blinded, case-control trial, the investigators will recruit 164 patients with atypical parkinsonism (either MSA or PSP) to investigate the efficacy and cost-effectiveness of a 12-month remote home-based integrated program to improve healthcare delivery, coordinated by a specialized nurse (case manager) compared to standard medical care. This organizational model of personalized medicine aims to simplify, standardize and improve patient care and monitoring over time, including remote management of situations of urgency. This telenursing program consists of both proactive and reactive monitoring approaches acting synergistically to optimize the continuity of care by tertiary expert movement disorders clinics. In proactive monitoring, patients are contacted at baseline (to create a patient record focused on identifying individual-specific vulnerabilities) and then every 3 months. During the 12-month study period, patients and caregivers may contact the case manager in case of any problems (reactive monitoring), who may: (a) deal with the specific problem also by interacting with the participant's general practitioner and other healthcare professionals (e.g. physical therapist, psychologist, nutritionist, occupational therapist, social worker, etc) or (b) refer to the neurologist for teleconsultation or in-person visit according to a semi-structured algorithm, which assigns 4 levels of priority. Participants will be evaluated with clinical scales testing the quality of life, motor and non-motor symptoms, caregiver burden, adherence to therapy, cumulative disease burden and the number of unscheduled hospital access during the study period. The cost-effectiveness of this method will also be evaluated by using the EuroQoL, which will estimate the incremental cost per quality-adjusted life-years (QALY) gain. Finally, the investigators will assess the feasibility and utility of Telemonitoring to guide decisionmaking by using a waist-worn wearable (STAT-ONTM) to monitor real-life motor autonomy and the risk of falls, including freezing of gait for 5 consecutive days every month during the 12-month duration of the study. If successful, this low-cost integrated management of patients with atypical parkinsonism may be extended to people with the more prevalent Parkinson's disease as well as other neurodegenerative disorders (e.g. Alzheimer's dementia)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations, Nurse Physician Relations
Keywords
Atypical parkinsonism, Nurse Specialist, MSA, PSP

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
164 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Telemonitoring
Arm Type
Experimental
Arm Description
Patients are followed up by a nurse-telemonitoring
Arm Title
Standard-of-care
Arm Type
Active Comparator
Arm Description
Patients are followed up only by the neurologist
Intervention Type
Other
Intervention Name(s)
Telemonitoring
Intervention Description
Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
Intervention Type
Other
Intervention Name(s)
Standard-of-care
Intervention Description
Patients are managed only by the neurologist according the institution's clinical practice
Primary Outcome Measure Information:
Title
Changes in total score of the Parkinson's Disease Questionnaire 39-items scale (PDQ-39)
Description
Thi is a 39-items questionnaire assessing the quality of life of patient with Parkinsonism. Score is expressed in percentage from 0% to 100%. The higher the score the lower the quality of life
Time Frame
baseline, week 52
Secondary Outcome Measure Information:
Title
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part II (MDS-UPDRS Part II)
Description
This is a scale (MDS-UPDRS Part II) used to assess activities of daily living. Score ranges from 0 to 52. The higher the score the worse the Disability
Time Frame
baseline, week 52
Title
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part IV (MDS-UPDRS part IV)
Description
This is a scale (MDS-UPDRS part IV) used to assess complications of dopaminergic therapy. Score ranges from 0 to 24. The higher the score the worse the disability
Time Frame
baseline, week 52
Title
Changes in the Non-Motor Symptoms Scale score (NMSS)
Description
This is a scale used to assess the burden of non-motor symptoms in Parkinson's disease. Total score is 0-360. The higher the score the worse the disability
Time Frame
baseline, week 52
Title
Changes in Unified Multiple System Atrophy Rating Scale (UMSARS)
Description
This scale (UMSARS) is used to assess disease progression in multiple system atrophy.The score is from 0 up to 109. The higher the score the worse the disability
Time Frame
baseline, week 52
Title
Changes in Progressive Supranuclear Palsy Rating Scale (PSPRS)
Description
This scale (PSPRS) is used to assess disease progression in Progressive Supranuclear Palsy. The total score is 0-100. The higher the score the worse the disability
Time Frame
baseline, week 52
Title
Changes in the activities of daily living questionnaire (ADL_questionnaire)
Description
The "ADL (Activities of Daily Living)" evaluation refers to the fundamental activities of daily life in which the subject is dependent: on a scale from 0 to 6 points, the lower the score, the greater the person's need for assistance
Time Frame
baseline, week 52
Title
Changes in the intrumental activities of daily living questionnaire (IADL)
Description
The "IADL (Instrumental Activities of Daily Living)" evaluation refers to the instrumental activities of daily life in which the subject is dependent (eg using telephone, preparing meals, taking medications, etc): on a scale from 0 to 8 points, the lower the score, the greater the person's need for assistance
Time Frame
baseline, week 52
Title
Changes in the Zarit Burden Interview scale score (ZBI)
Description
This is a scale used to investigate caregiver's burnout. Total score is 0-40. The higher the score the worse the disability
Time Frame
baseline, week 52
Title
Number of unplanned hospital admission
Description
Sum of number of outpatients departments assessments, number of emergency rooms accesses, number of unplanned hospitalizations
Time Frame
week 52
Title
Number of incident comorbidities
Description
The number of incident comorbidities over the 12.month study period will be assessed using a semistructured interview
Time Frame
baseline, week 52
Title
Changes in Euro Quality Of Life Dimensions-5 Levels score (EuroQOL-5)
Description
This is a useful and validated instrument to measure quality of life in patients with Parkinson's disease. The patient select a score from 0 to 100. The lowest the score the lowest quality of life.
Time Frame
baseline, week 52
Title
Changes in the Morisky Medical Adherence scale-8 items score (MMAS)
Description
This is an 8-items scale used to investigate patient adherence to the therapy prescribed by the MD specialist. Score is 0-8 "yes" answer. The 3 categorical Likert Scale is: low adherence <6; medium adherence 6-8; high adherence 8.
Time Frame
baseline, week 26, week 52
Title
Changes in patient experience questionnaire (EQ)
Description
This is a questionnaire assessing patient perception and satisfaction of the quality of health care. Total score is 0-100. The highest the score, the worst the satisfaction
Time Frame
baseline, week 26, week 52
Title
Changes in freezing of walking, Freezing of gait-questionnaire (FOG-Q)
Description
Changes in gait performances, mainly in freezing of walking, are analysis by this questionnaire. Total score is 0-24. The highest the score, the highest the freezing
Time Frame
baseline, week 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of MSA or PSP in all their possible variants (MSA-P, MSA-C; PSP-RS, PSP-P, PSP-CBS, etc.) according to internationally validated criteria. Exclusion Criteria: Hoehn and Yahr stage = 5 in ON phase Clinical Frialty Scale (CFS) ≥ 8 Serious medical disorders that, in the opinion of the recruiting neurologist, may impair participation in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Roberto Cilia, MD
Phone
(+39)0223941
Ext
2552
Email
neuro1@istituto-besta.it
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Research Center, CRC
Phone
(+39)0223941
Ext
3568
Email
crc@istituto-besta.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto Eleopra, MD
Organizational Affiliation
Study Principal Investigator Fondazione IRCCS Istituto Neurologico Carlo Besta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda Ospedaliera Universitaria Gaetano Martino
City
Messina
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmen Terranova
Facility Name
Fondazione IRCCS Istituto Neurologico Carlo Besta
City
Milan
ZIP/Postal Code
20133
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto Cilia, MD
Phone
(+39)0223941
Ext
2552
Email
roberto.cilia@istitutobesta.it
Facility Name
Fondazione IRCCS Istituto Neurologico Nazionale Casmiro Mondino
City
Pavia
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesca Valentino, MD
Facility Name
IRCCS Neuromed
City
Pozzilli
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data obtained through this study may be provided to qualified researchers with academic interest on this topic. Data shared will be coded, with no protected health information included. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis
IPD Sharing Access Criteria
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. For more information or to submit a request, please contact crc@istituto-besta.it
Citations:
PubMed Identifier
23165981
Citation
van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord. 2013 May;28(5):605-11. doi: 10.1002/mds.25194. Epub 2012 Nov 19.
Results Reference
background
PubMed Identifier
16007641
Citation
Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609.
Results Reference
background
PubMed Identifier
22400982
Citation
Gerlach OH, Broen MP, van Domburg PH, Vermeij AJ, Weber WE. Deterioration of Parkinson's disease during hospitalization: survey of 684 patients. BMC Neurol. 2012 Mar 8;12:13. doi: 10.1186/1471-2377-12-13.
Results Reference
background
PubMed Identifier
26803377
Citation
Muzerengi S, Herd C, Rick C, Clarke CE. A systematic review of interventions to reduce hospitalisation in Parkinson's disease. Parkinsonism Relat Disord. 2016 Mar;24:3-7. doi: 10.1016/j.parkreldis.2016.01.011. Epub 2016 Jan 13.
Results Reference
background
PubMed Identifier
23835430
Citation
Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, Giladi N, Bloem BR, Malaty IA, Okun MS; NPF-QII Investigators. High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease. Parkinsonism Relat Disord. 2013 Nov;19(11):949-54. doi: 10.1016/j.parkreldis.2013.06.006. Epub 2013 Jul 5.
Results Reference
background
PubMed Identifier
9351479
Citation
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997 Sep;26(5):353-7. doi: 10.1093/ageing/26.5.353.
Results Reference
background
PubMed Identifier
27810571
Citation
Hagell P, Alvariza A, Westergren A, Arestedt K. Assessment of Burden Among Family Caregivers of People With Parkinson's Disease Using the Zarit Burden Interview. J Pain Symptom Manage. 2017 Feb;53(2):272-278. doi: 10.1016/j.jpainsymman.2016.09.007. Epub 2016 Nov 1.
Results Reference
background
PubMed Identifier
1594710
Citation
Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992 Mar;41(3):237-48. doi: 10.1016/0165-1781(92)90005-n.
Results Reference
background
PubMed Identifier
10864606
Citation
Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73. doi: 10.1136/jnnp.69.1.67.
Results Reference
background
PubMed Identifier
23728715
Citation
Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, Rizzoli S, Morisky DE, Lessi P, Ceravolo R; REASON study group. Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". Neurol Sci. 2013 Nov;34(11):2015-22. doi: 10.1007/s10072-013-1438-1. Epub 2013 Jun 1.
Results Reference
background
PubMed Identifier
35445419
Citation
Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Hoglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022 Jun;37(6):1131-1148. doi: 10.1002/mds.29005. Epub 2022 Apr 21.
Results Reference
background
PubMed Identifier
16129869
Citation
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.
Results Reference
background
PubMed Identifier
35062375
Citation
Borzi L, Mazzetta I, Zampogna A, Suppa A, Irrera F, Olmo G. Predicting Axial Impairment in Parkinson's Disease through a Single Inertial Sensor. Sensors (Basel). 2022 Jan 6;22(2):412. doi: 10.3390/s22020412.
Results Reference
background
PubMed Identifier
32723588
Citation
Cilia R, Mancini F, Bloem BR, Eleopra R. Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. Parkinsonism Relat Disord. 2020 Jun;75:130-132. doi: 10.1016/j.parkreldis.2020.05.038. Epub 2020 Jun 10.
Results Reference
background
PubMed Identifier
28800338
Citation
Lennaerts H, Groot M, Rood B, Gilissen K, Tulp H, van Wensen E, Munneke M, van Laar T, Bloem BR. A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. J Parkinsons Dis. 2017;7(4):749-754. doi: 10.3233/JPD-171195.
Results Reference
result

Learn more about this trial

Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)

We'll reach out to this number within 24 hrs